<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The impact of first- and subsequent-cycle growth factor use in the community setting has not been studied extensively </plain></SENT>
<SENT sid="1" pm="."><plain>We conducted this large, prospective, noncomparative study to assess <z:hpo ids='HP_0001875'>neutropenia</z:hpo> and related complications in patients receiving myelotoxic chemotherapy with pegfilgrastim support in community practices </plain></SENT>
<SENT sid="2" pm="."><plain>Patients &gt; or = 18 years old with <z:e sem="disease" ids="C1707251" disease_type="Neoplastic Process" abbrv="">cancers other</z:e> than <z:hpo ids='HP_0001909'>leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, including those with major comorbidities, were eligible </plain></SENT>
<SENT sid="3" pm="."><plain>Pegfilgrastim (6 mg) was to be administered approximately 24 hours after chemotherapy in <z:hpo ids='HP_0000001'>all</z:hpo> cycles (minimum, four cycles) </plain></SENT>
<SENT sid="4" pm="."><plain>A total of 2,112 patients was included in the analyses </plain></SENT>
<SENT sid="5" pm="."><plain>The most <z:e sem="disease" ids="C1333132" disease_type="Neoplastic Process" abbrv="">common tumor</z:e> types were <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (46%), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (15%), and <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e> (13%) </plain></SENT>
<SENT sid="6" pm="."><plain>Chemotherapies administered most often were a <z:chebi fb="240" ids="33364,33400">platinum</z:chebi> plus a <z:chebi fb="0" ids="36064">taxane</z:chebi> (18%), and <z:chebi fb="0" ids="48120">anthracycline</z:chebi> plus an <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> (18%), and a <z:chebi fb="0" ids="36064">taxane</z:chebi> plus an <z:chebi fb="0" ids="48120">anthracycline</z:chebi> plus an <z:chebi fb="0" ids="22333">alkylating agent</z:chebi> (16%) </plain></SENT>
<SENT sid="7" pm="."><plain>The percentage of patients with <z:hpo ids='HP_0001875'>neutropenia</z:hpo>-related hospitalization was 2.9% in cycle 1 and 5.6% across <z:hpo ids='HP_0000001'>all</z:hpo> cycles </plain></SENT>
<SENT sid="8" pm="."><plain>Chemotherapy dose reductions and delays were attributed to <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 1.8% and 0.9% of patients, respectively, in cycle 2 and 2.9% and 2.1% of patients, respectively, across <z:hpo ids='HP_0000001'>all</z:hpo> cycles </plain></SENT>
<SENT sid="9" pm="."><plain>Febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (absolute neutrophil count &lt;1.0 x 10(9)/l with temperature &gt; or = 38.2 degrees C) occurred in 3.6% of patients in cycle 1 and in 6.3% of patients across <z:hpo ids='HP_0000001'>all</z:hpo> cycles </plain></SENT>
<SENT sid="10" pm="."><plain>The most frequently reported serious adverse events were febrile <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (3.4%), <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (2.6%), and <z:hpo ids='HP_0001944'>dehydration</z:hpo> (2.6%) </plain></SENT>
<SENT sid="11" pm="."><plain><z:hpo ids='HP_0002653'>Bone pain</z:hpo> (0.1%) was the only related serious adverse event reported in more than one patient </plain></SENT>
<SENT sid="12" pm="."><plain>Data from this community-based study suggest that patients undergoing chemotherapy benefit from pegfilgrastim support beginning in the first cycle of chemotherapy </plain></SENT>
</text></document>